These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7527427)

  • 21. Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates.
    Eron JJ; Gorczyca P; Kaplan JC; D'Aquila RT
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3241-5. PubMed ID: 1565615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
    Palmer S; Harmenberg J; Cox S
    Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
    Gu Z; Gao Q; Faust EA; Wainberg MA
    J Gen Virol; 1995 Oct; 76 ( Pt 10)():2601-5. PubMed ID: 7595365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
    Rooke R; Parniak MA; Tremblay M; Soudeyns H; Li XG; Gao Q; Yao XJ; Wainberg MA
    Antimicrob Agents Chemother; 1991 May; 35(5):988-91. PubMed ID: 1649576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
    Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
    Shafer RW; Kozal MJ; Katzenstein DA; Lipil WH; Johnstone IF; Merigan TC
    J Virol Methods; 1993 Mar; 41(3):297-310. PubMed ID: 8097199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
    Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
    J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
    Xie H; Voronkov M; Liotta DC; Korba BA; Schinazi RF; Richman DD; Hostetler KY
    Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues.
    Stuyver LJ; Lostia S; Adams M; Mathew JS; Pai BS; Grier J; Tharnish PM; Choi Y; Chong Y; Choo H; Chu CK; Otto MJ; Schinazi RF
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3854-60. PubMed ID: 12435688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
    Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate.
    Rusconi S; De Pasquale MP; Milazzo L; Bulgheroni E; Citterio P; Kurtagic S; d'Arminio-Monforte A; Galli M
    AIDS; 1997 Sep; 11(11):1406-10. PubMed ID: 9302459
    [No Abstract]   [Full Text] [Related]  

  • 38. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
    Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P; Danner SA; Mulder J; Loveday C; Christopherson C
    J Infect Dis; 1995 Jun; 171(6):1411-9. PubMed ID: 7539472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
    Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.